logo

For the Inventor, By the Inventor

Norcross, GA, United States of America

Sivaram Pillarisetti

This inventor holds 32 USPTO granted patents and 5 published patent applications and 3 EPO patents, primarily in Pharmaceutical Compositions. Top assignees: Reddy US Therapeutics, Inc., Dr. Reddy's Laboratories, Incorporated, Nephrodi Therapeutics, Inc.. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sivaram Pillarisetti. Retrieved from https://idiyas.com/inventor/sivaram-pillarisetti

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 32 

% Patents Active = 15.6

 

Average Co-Inventor Count = 4.9

ph-index = 7

Forward Citations = 219(Granted Patents)


Company Filing History:

goldMedal17 out of 19 
 
Reddy US Therapeutics, Inc.
 patents
silverMedal7 out of 187 
 
Dr. Reddy's Laboratories, Incorporated
 patents
bronzeMedal2 out of 2 
 
Nephrodi Therapeutics, Inc.
 patents
4. 2 out of 2 
 
North Shore-Long Island Jewish Health System
 patents
5. 1 out of 1,024 
 
Emory University
 patents
6. 1 out of 3 
 
Kareus Therapeutics, Sa
 patents
7. 1 out of 21 
 
North Shore-Long Island Jewish Research Institute
 patents
8. 1 out of 1 
 
Reddy U5 Therapeutics, Inc.
 patent

Years Active: 2003-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
Cholesterol Ester-Transfer Protein
Substituted Cycloalkanes
Diabetes Treatment
Dyslipidemia
Triazine Compounds
GATA Modulators
Heterocyclic Compounds
Small-Molecule Modulators
Inflammatory Diseases
Cellular Proliferation
Angiogenesis
Glycosidase Assays
32 patents (USPTO):Explore Patents
1. 12433858 - Substituted cycloalkanes for managing nephrogenic diabetes insipidus (2025-10-07),
2. 11844770 - Substituted cycloalkanes for managing nephrogenic diabetes insipidus (2023-12-19),
3. 11179354 - Substituted cycloalkanes for managing nephrogenic diabetes insipidus (2021-11-23),
4. 9782407 - Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors (2017-10-10),
5. 9765030 - Benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors (2017-09-19),
6. 9040558 - Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors (2015-05-26),
7. 8623897 - Methods and compositions for treatment of diabetes and dyslipidemia (2014-01-07),
8. 8604055 - Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors (2013-12-10),
9. 8008328 - Methods for the treatment of diabetes-associated dyslipdemia (2011-08-30),
10. 7989463 - Biccyclic compounds as GATA modulators (2011-08-02),
11. 7820654 - Pyrimidine compounds, process for their preparation and compositions containing them (2010-10-26),
12. 7700774 - Heterocyclic compounds and their pharmaceutical compositions (2010-04-20),
13. 7335770 - Triazine compounds and their analogs, compositions, and methods (2008-02-26),
14. 7335656 - Medical devices employing triazine compounds and compositions thereof (2008-02-26),
15. 7332490 - Methods and compositions of novel triazine compounds (2008-02-19),

Title: Innovator Spotlight: Sivaram Pillarisetti, Pioneering Solutions for Nephrogenic Diabetes Insipidus

Introduction:

Sivaram Pillarisetti, a prolific inventor based in Norcross, GA, has made significant contributions to the field of healthcare with his groundbreaking patents. With an impressive portfolio of 31 patents, Pillarisetti's innovative solutions are revolutionizing the treatment of nephrogenic diabetes insipidus.

Latest Patents:

Pillarisetti's latest patents focus on the development of substituted cycloalkanes for managing nephrogenic diabetes insipidus. These patents entail methods for treating and preventing the condition by administering specific compounds to individuals diagnosed with nephrogenic diabetes insipidus. The compounds offer a promising avenue for addressing this challenging medical condition.

Career Highlights:

Throughout his career, Pillarisetti has been associated with prestigious companies such as Reddy US Therapeutics, Inc. and Dr. Reddy's Laboratories, Incorporated. His expertise and ingenuity have played a vital role in advancing the pharmaceutical industry, particularly in the realm of treating complex health conditions.

Collaborations:

Pillarisetti has collaborated with esteemed professionals in the field, including Christopher W Alexander and Uday Saxena. These collaborations have been instrumental in fostering innovation and bringing cutting-edge solutions to the forefront of healthcare.

Conclusion:

In conclusion, Sivaram Pillarisetti's inventive spirit and dedication to improving healthcare outcomes have established him as a trailblazer in the field of pharmaceutical innovation. His patents on substituted cycloalkanes for managing nephrogenic diabetes insipidus underscore his commitment to driving positive change and revolutionizing medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…